StoneX Group’s Zosano Pharma Corporation ZSAN Stock Holding History

StoneX Group’s Portfolio ZSAN Stock Details ZSAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,090	Closed	-$34.4K	–	687
2021 Q4	$34.4K	Buy	+2,090	New	+$44.1K	﹤0.01%	554

Other funds holding ZSAN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CDIA

Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

StoneX Group's ZSAN Position: Q1 2022 in Review

StoneX Group sold out of Zosano Pharma Corporation (ZSAN) in Q1 2022, closing a stake of 2,090 shares — an estimated $34.4K sold.

StoneX Group first reported a position in ZSAN in Q4 2021 and held it in 1 quarter. The position peaked at $34.4K in Q4 2021. 30 funds tracked by Wall St. Rank hold ZSAN as of Q1 2022.

StoneX Group reported no remaining Zosano Pharma Corporation position as of Q1 2022 after selling out during the quarter.
StoneX Group sold 2,090 Zosano Pharma Corporation shares in Q1 2022, an estimated $34.4K.
StoneX Group first reported a position in Zosano Pharma Corporation in Q4 2021 and held it in 1 quarter.
StoneX Group's Zosano Pharma Corporation position peaked at $34.4K in Q4 2021.
30 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q1 2022.

Based on StoneX Group's 13F filing for Q1 2022, filed 11 May 2022.